Sickle Cell Anemia Testing and Screening Market has gained significance due to the increasing emphasis on early detection and diagnosis of sickle cell anemia in today’s healthcare landscape by the government, laboratories, and healthcare organizations. In contrast to traditional methods of diagnosis which may include several steps, modern screening techniques allow for faster detection of the disease and its carriers using hemoglobin tests, molecular tests, POCTs, and AI-aided blood smear tests.
The Sickle Cell Anemia Testing and Screening Market has been valued at USD 494.8 million in 2025 and is projected to reach USD 1,579 million by 2035, witnessing a CAGR of 12.30% during 2026-2035, according to SNS Insider. The market size is forecasted to be around USD 554.5 million in 2026. Factors such as the rising prevalence of sickle cell disorder, the increasing number of government-supported screening programs for newborns and the general population and advancements in diagnostic technology that help increase accuracy, decrease testing time, and reduce costs will drive growth. Sickle cell disorder is diagnosed in about 300,000 newborns yearly and the figure is predicted to touch 400,000 by 2050.
Gain Actionable Intelligence on this Market – Request a Sample Report
Top 3 Sickle Cell Anemia Testing and Screening Companies
1. Bio-Rad Laboratories Inc.
One of the leading firms in the Sickle Cell Anemia Testing and Screening Market includes Bio-Rad Laboratories owing to their offerings of hemoglobin analysis and newborn screening products. VARIANT HPLC instruments by the firm are useful in detecting various hemoglobin variants and can be utilized in high-throughput testing situations. VARIANT System enhancements are helping to make laboratory operations better through improved automation and work flow and hemoglobin variant detection. Growing initiatives by governments for newborn screening will create a steady demand for HPLC platforms due to the need for efficient hemoglobin variant detection in central laboratories dealing with large numbers of newborns. In 2026, Bio-Rad was able to increase the adoption of its VARIANT HPLC platform in high-throughput newborn screening applications.
2. Thermo Fisher Scientific Inc.
The company has made a strong presence in the market through its molecular diagnostics, blood typing, and laboratory technology. With the advancement in sickle cell disease treatment through more personalized approach, the diagnostic services of Thermo Fisher Scientific become more important. The company's array-based extended blood typing solutions can help in conducting a thorough patient evaluation, especially where advanced treatments need clinical and genetic details. The company will also gain due to rising demands for molecular test, carrier detection, and diagnostic tests related to gene therapy. The development of laboratory technologies would continue to make the company strong during the forecast period. During 2026, the company has continued to expand extended blood typing and molecular diagnostic services.
3. Abbott Laboratories
Abbott Laboratories continues to play a role in increasing access to sickle cell tests through its extensive diagnostic product line and decentralized healthcare technology initiatives. Point of care testing is especially relevant in places that lack centralized laboratory facilities. Rapid diagnostic test kits have the potential to help perform screening procedures in community healthcare clinics, rural health centers and other places where laboratory-based screening tests might not be easy to perform. Abbott Laboratories' continued efforts in developing portable diagnostic tools correlate with the current market trend of faster testing and increased accessibility of testing. In 2026, Abbott continues to expand point of care hematology diagnostic options in community healthcare centers.
What is Driving the Future of the Sickle Cell Anemia Testing and Screening Market?
The growing prevalence of sickle cell disease ranks among the most compelling drivers of market growth. Higher prevalence of the disease is prompting authorities to improve their programs related to newborn, population, and carrier screenings. Screening is especially critical at an early stage as this will allow preventive measures to be undertaken before the emergence of complications. The introduction of screening requirements by the government in countries such as the US, UK, and France has contributed to a steady demand for testing equipment.
Innovation in technology is changing the way sickle cell disease is detected. Point of care rapid lateral flow tests take just about 10-15 minutes using the finger-stick method of blood sampling, without the requirement of a highly complex laboratory infrastructure. This method is particularly useful in remote areas and high prevalence areas of sub-Saharan Africa and India. Examples of rapid tests include HemoTypeSC and Sickle SCAN. High Performance Liquid Chromatography is essential for large scale screening because it allows for the rapid identification of various types of hemoglobins in a centralized laboratory setting. At the same time, molecular diagnostics using DNA with PCR and sequencing gives accurate genotyping information. These developments demonstrate how the emergence of advanced sickle cell treatments is expanding diagnostic demand beyond initial disease identification.
The Road Ahead
The future of the market of Sickle Cell Anemia Testing & Screening will be affected by the confluence of broadened programs of neonatal screening, decentralized tests, molecular diagnosis, analysis by means of artificial intelligence, and demands on diagnosis as a result of gene therapy. Point-of-care devices will be among the most revolutionary developments due to their ability to provide quick screening for patients who reside in those areas where laboratories lack infrastructure. Gene therapy will change the needs in diagnosis through the creation of a need throughout the entire patient’s journey – from the confirmation of the condition and qualification to follow-up after treatment.
In general, there is an increasing trend towards the development of diagnostic tests that would be accurate, fast, cheap, automated, and convenient. Companies which can offer diagnostic solutions which work in central laboratories as well as decentralized health care systems have good chances to take advantage of the expected 12.30% CAGR of the market until 2035. With the increase of screening and availability of new treatments, diagnostic tests will play an important role in sickle cell disease management.
